Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

ally to assess the safety of ISIS 301012 in HoFH and in combination with high-dose concurrent lipid-lowering therapies, the protocol initially called for five weeks of dosing. Based on a strong safety profile at five weeks with doses through 200 mg/week, the study was amended to include a cohort of patients dosed at 300 mg/week for three months, and it is that cohort for which Isis is updating the interim data presented at the ACC. Because HoFH is an extremely rare condition affecting one person per million, clinical trials in this disease are generally quite small.

The study included three HoFH patients with very high incoming LDL-cholesterol levels despite being treated with maximally-tolerated lipid-lowering therapies. Throughout the study, all patients remained on their other lipid-lowering drugs at constant doses. With this update, all patients completed 12 weeks of study treatment and reached the primary endpoint for analysis at Day 99, 14 days after receiving their last dose of ISIS 301012. The patients continue in follow-up. The data are summarized in tabular form below.



    Table 1: ISIS 301012 in HoFH, Summary of Results

    Lipid values are presented in mg/dL and % change from baseline.


                  Patient 1         Patient 2          Patient 3


                                      80 mg

                                   atorvastatin +

    Concurrent                   10 mg ezetimibe +

    Lipid-                            3.75 g              40 mg

    lowering        80 mg          colesevelam +      rosuvastatin +

    Therapies    atorvastatin       1 g niacin        10 mg ezetimibe


    Age

     (years)        23                  48                  32


    Lipids: Base-   Day    %     Base- Day    %     Base-  Day    %

            line    99   change  line  99   change  line   99   change

    ApoB     369    171   -54%   180   103   -43%   283    156   -45%

    LDL-C    651    318   -51%   197    99   -50%   4
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is ... (FDA) issued a warning letter to C.R. Bard, the manufacturer ... taking adequate strides to correct violations the agency found at ... these violations after the FDA cited them during Inspectional Observations ... in Bard,s Tempe, AZ , location and ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
(Date:8/3/2015)... , ... August 03, 2015 , ... ... brokerage firm, announced today that Joe Williams has joined its growing California employee ... delivering HUB's differentiated service model to his clients. Mr. Williams will be joining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... ... 03, 2015 , ... Career Step, an online institution offering ... for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on Friday ... AHDI conference provides us to interact with those in the healthcare documentation industry,” ...
(Date:8/2/2015)... (PRWEB) , ... August 02, 2015 , ... Molecular biologists ... powerful prognostic indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the ... University of New South Wales tested for Ki67 expression in tissue samples from 42 ...
(Date:8/1/2015)... ... 2015 , ... Have you ever wondered what “Karma” really means? Does it even exist? Can ... , Vedic tradition, which gave birth to Hinduism, is one of the most ancient spiritual ... this tradition. According to the wisdom of this heritage, Karma is a very real and ...
Breaking Medicine News(10 mins):Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2
... ... with Alzheimer,s disease and disabilities, and a decreasing work force to care for them, threatens ... care business owner. , ... NE (PRWEB) September 29, 2009 -- A crisis in aging, fueled by increasing numbers of ...
... ... foot and ankle Pain." Claims Dr. Katz , ... Tampa, FL (PRWEB) September 29, 2009 -- Foot pain and foot ... of solutions for their foot and ankle pain and are growing frustrated with continuous visits ...
... study by researchers at The George Institute for International Health ... to PCPs with acute lower back pain to have previously ... documented was vertebral fracture, with half of the cases identified ... in the October issue of Arthritis & Rheumatism , ...
... shoe choices early in life suffer with foot pain in later ... foot pain as women, due to type of shoes they wear. ... Arthritis Care & Research , a journal published by Wiley-Blackwell ... reveal that foot and toe symptoms are among the top 20 ...
... cancer with the Prostate Specific Antigen (PSA) test in ... becomes symptomatic, knowing whether screening is beneficial for these ... or no reductions in prostate cancer mortality among those ... against the more common and immediate downsides of increasing ...
... at Harbor-UCLA Medical Center (LA BioMed) will honor Los Angeles ... founder and president of Kakkis EveryLife Foundation, as its "Spirit ... 6 at the Terranea Resort in Rancho Palos Verdes. ... for the excellence each represents in his chosen field," said ...
Cached Medicine News:Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 2Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 3Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 4Health News:Dr. Marc Katz, Leading Podiatric Surgeon Adds High Powered Color Ultrasound To Cryosurgery Procedures and Treatments 2Health News:PCPs are front line defense in diagnosing serious illness in patients with acute lower back pain 2Health News:Women who make poor shoe choices at risk for foot pain later in life 2Health News:UNC expert: Better decision support tools needed for prostate cancer screening choice 2Health News:LA BioMed to honor Emil D. Kakkis, M.D., Ph.D., and LA County Supervisor Don Knabe 2
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... to dry trays to specialty vaginal & ... Health offers the widest offering in patient ... that are proven to be safe and ... surgical site infections. Cardinal Health Scrub Care ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... The Anti-HTLV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... assays. Comprehensive data from all major test ...
Medicine Products: